{
  "docId": "019de076-3deb-7779-9c43-c38f834a1cfd",
  "docSlug": "60ad9a5894e93b6af8b1b5bddd2d87e3",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 30 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 30,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 128,
  "notes": "Includes specific highlighting boxes (green, yellow, red) around data subsets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3deb-7779-9c43-c38f834a1cfd/26",
  "deckHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd",
  "deckJsonHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd.json",
  "deckAnchorHref": "/decks/019de076-3deb-7779-9c43-c38f834a1cfd#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.03,
        "y": 0.62
      },
      "kind": "list",
      "text": "Blood count changes were the only dose-dependent adverse events. No Dose-Limiting Toxicities (DLTs) were observed at dose levels of 10-40 kBq/kg (hot only). DLTs of Grade 4 thrombocytopenia were reported in 2 patients at dose levels of 55 and 75 kBq/kg (hot only). No DLTs were observed with cold/hot dosing regimen at 15kbq. Grade 1 thrombocytopenia reported in 1 of 3 patients. No significant effect on biomarkers related to IGF-1R pathway.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18688064-f527-45f2-9203-e1492918569f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Adverse events table by preferred term and dosage cohort",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bef7f112-b365-414c-bac2-ce43a4e05d81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "FPI-1434 Phase 1 Trial Preliminary Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aae7169d-f8f1-4e55-b31d-be0ef070f22f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "95a22ef9-83a0-4347-93dc-3ef7c8c3d68b",
      "evidence": "The slide presents a list of bullet points summarizing the preliminary safety summary of the FPI-1434 Phase 1 Trial.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}